WELCOME  to the Hulme Research Group

    The mission of our laboratory is to pursue excellence in teaching, outreach and research in both medicinal chemistry and drug development. The Hulme lab provides resources - expertise, equipment and chemists - for University of Arizona faculty and pharmaceutical industry partners, with the purpose of developing novel therapeutics. Our goal is to enhance access to medicinal chemistry and drug discovery education through excellence in research and training.

    An immense opportunity has been created to improve both human health and longevity. The various roles of the multitude of newly-discovered macromolecules involved in disease progression may now be investigated by the preparation of small molecule libraries and the development of targeted molecular probes. Once identified, these small molecules might, ultimately, be the precursors to disease-modifying drugs to address currently unmet medical needs.
read more

The Research

The Hulme Research Group develops novel small molecule libraries with exceptional potency and selectivity to explore multiple therapeutic areas. Our group has recently developed and validated a process work flow that will create small and large libraries of novel compounds to be used in biochemical and biological screenings as part of the drug discovery process.

    These libraries will help facilitate the promise of chemical biology - unearthing quality small molecule probes to elucidate the physiological roles of proteins of otherwise unknown function. Our research group has complementary skill sets in multiple functional areas, with a depth of expertise in high-throughput medicinal chemistry and drug design principles spanning both academic and industrial settings.

The Potential

Novel molecular scaffolds are selected for strong biological rationale, often taking advantage of crucial molecular recognition motifs of multiple target families. All scaffolds are unique and viewed as structurally compelling. Success in structure-activity studies will be facilitated by selection of scaffolds possessing 'High Iterative Efficiency Potential' that 1) Improve the iterative speed of the medicinal chemist navigating the 'hypothesis-synthesis-screening' loop and 2) Reduce the number of required iterations for milestone progression. The Hulme group libraries will present new opportunities for therapeutic advancement in multiple disease investigations.
read more